Hamad Medical Corporation

Recipients of the 2024 ACGME International Awards Announced

Retrieved on: 
Monday, September 25, 2023
MBBS, FRCS, Accreditation, 21st Century Leaders Awards, FCPS, Hamad Medical Corporation, Global health, GME, Gynaecology, Patient, Physician, FACS, Obstetrics, Faculty, Aga Khan University, Conference, Nursing

Chicago, IL, Sept. 25, 2023 (GLOBE NEWSWIRE) -- ACGME International (ACGME-I) is proud to announce the winners of the 2024 ACGME International Awards.

Key Points: 
  • Chicago, IL, Sept. 25, 2023 (GLOBE NEWSWIRE) -- ACGME International (ACGME-I) is proud to announce the winners of the 2024 ACGME International Awards.
  • These awards celebrate individuals who have shown extraordinary dedication to graduate medical education (GME).
  • Dr. Khan is professor of surgery and associate dean for postgraduate medical education at Aga Khan University, Karachi, Pakistan.
  • ACGME International (ACGME-I) is an independent 501(c)(3) organization currently providing accreditation services to 181 graduate medical education programs in 22 institutions across 12 countries.

ACGME International Continues to Grow, Begins Accreditation Activities in Vietnam

Retrieved on: 
Thursday, August 10, 2023
Partnership, Accreditation, Hamad Medical Corporation, Pediatrics, Pathology, ACGME, Global health, Aga Khan University, Jordan University of Science and Technology, GME, Radiology, Gynaecology, Dermatology, Physician, Outline of health sciences, Obstetrics, Neurology, Anesthesiology, Nursing, MD

ACGME-I accreditation activities expand to 12 countries as VinUni College of Health Sciences in Hanoi becomes the first Sponsoring Institution in Vietnam to achieve ACGME-I accreditation.

Key Points: 
  • ACGME-I accreditation activities expand to 12 countries as VinUni College of Health Sciences in Hanoi becomes the first Sponsoring Institution in Vietnam to achieve ACGME-I accreditation.
  • Finally, GME programs in two long-standing Sponsoring Institutions in Qatar – dermatology at Hamad Medical Corporation and pediatric anesthesiology at Sidra Medicine – also achieved Initial Accreditation.
  • Over the past five years, ACGME-I accreditation activities have grown significantly, doubling the number of countries and accredited GME programs.
  • Its mission is to improve health care by assessing and advancing the quality of resident physicians’ education through accreditation.

ZOLL remedē System, a Breakthrough Therapy for Treating Central Sleep Apnea, Receives Approval for MRI Conditional Use

Retrieved on: 
Wednesday, May 24, 2023
Other Health, Radiology, Hardware, Medical Devices, Technology, Health Technology, Cardiology, Biotechnology, Neurology, Other Technology, FDA, Health, Life, Central sleep apnea, CSA, Respiration, Diaphragm, Spine, Asahi Kasei, Brain, MRI, Magnetic resonance imaging, Patient, Hamad Medical Corporation, Phrenic nerve, Longevity, Medical imaging, Medical device

ZOLL’s remedē System is an implantable transvenous phrenic nerve stimulation therapy for the treatment of adults with moderate to severe Central Sleep Apnea (CSA).

Key Points: 
  • ZOLL’s remedē System is an implantable transvenous phrenic nerve stimulation therapy for the treatment of adults with moderate to severe Central Sleep Apnea (CSA).
  • Full-body MRI approval applies to all models of remedē System, covering new remedē patients as well as those who already have a remedē device.
  • Approval of the remedē System for conditional use with MRI will allow those patients to now have access to this important therapy,” said Dr. Asim Roy, medical director of the Ohio Sleep Medicine Institute.
  • FDA approval to use full-body MRI on remedē patients is a significant milestone for ZOLL and the remedē therapy.”
    The remedē System was approved by the FDA in 2017.

NeOnc Technologies Appoints Sidra Medicine CEO and Forbes Top 100 Healthcare Leader, Dr. Iyabo Tinubu-Karch, to Scientific Advisory Board

Retrieved on: 
Tuesday, April 18, 2023
Learning, Qatar Foundation, Central nervous system, University, Therapy, Education, Health, Hamad Medical Corporation, Weill Cornell Medicine, Prognosis, Research, Brain, CNS, Medicine, Public health, Hospital medicine, Patient, Swedish Health Services, Veterans' affairs, Swedish Medical Center (Colorado), St. Cloud VA Health Care System, United States Department of Veterans Affairs, Society, Geriatrics, Pharmaceutical industry, Medical device, Management, Sidra

The company’s scientific advisory board , now comprised of five global healthcare leaders, provides NeOnc management with valuable guidance and perspectives on product development, clinical trials, regulatory compliance, and biotech commercialization strategies.

Key Points: 
  • The company’s scientific advisory board , now comprised of five global healthcare leaders, provides NeOnc management with valuable guidance and perspectives on product development, clinical trials, regulatory compliance, and biotech commercialization strategies.
  • Ranked #58 on Forbes’ list of Top 100 Healthcare Leaders in the Middle East in 2023, Dr. Tinubu-Karch brings more than 26 years of healthcare leadership and executive experience to the board.
  • She currently serves as CEO of Sidra Medicine , a 400-bed women’s and children’s hospital, medical education and biomedical research center located in Doha, Qatar.
  • She also previously served as a Sidra Medicine board member and advisor on its management committee.

Results from Benefit of Microcor in Acute Decompensated Heart Failure (BMAD) Trial Presented as ACC.23/WCC Late-Breaking Clinical Trial

Retrieved on: 
Monday, March 6, 2023
Cardiology, Software, Biotechnology, Health, FDA, Medical Devices, Technology, Clinical Trials, Penn State Milton S. Hershey Medical Center, Penn State Health Children's Hospital, MD, Asahi Kasei, Hospital, Physician, Mortality, BMAD, Paul Zoll, Clinical trial, World Heart Federation, Patient, Benefit, Heart failure, Hamad Medical Corporation, American College, Syndrome, Pharmaceutical industry, Medical device

Based on BMAD Trial results, ZOLL Heart Failure Management System (ZOLL HFMS) reduced 90-day heart failure hospital readmission by 38% (p=0.03).1 To learn more, view BMAD Trial clinical results .

Key Points: 
  • Based on BMAD Trial results, ZOLL Heart Failure Management System (ZOLL HFMS) reduced 90-day heart failure hospital readmission by 38% (p=0.03).1 To learn more, view BMAD Trial clinical results .
  • ZOLL HFMS is non-invasive and can be worn by patients 24 hours a day.
  • Certified technicians from the ZOLL Independent Diagnostic Testing Facility monitor data from ZOLL HFMS and provide physicians with timely notifications based on patient-specific trends according to predefined criteria.
  • The system is intended for patients following an acute heart decompensation event that resulted in a hospitalization or clinic visit.

17th Edition of Digital Transformation Summit: Qatar

Retrieved on: 
Wednesday, March 1, 2023
Cloud, Knowledge, Al Jazeera Media Network, Senior, LIBF, Qatar National Vision 2030, Internet of things, Assistant, National data protection authority, University of the Arts London, Digital, Summit, Scottish Aquaculture Innovation Centre, Liability (financial accounting), Intelligent automation, Hamad Medical Corporation, The London Institute of Banking & Finance, Management

The 17th Edition of Digital Transformation Summit Qatar is taking place on 16th of March 2023 at The Westin Doha Hotel & Spa.

Key Points: 
  • The 17th Edition of Digital Transformation Summit Qatar is taking place on 16th of March 2023 at The Westin Doha Hotel & Spa.
  • At the summit, you will hear from top IT experts on emerging technologies, strategies, action plans and best practices towards building an agile digital organization.
  • "Organizational digital transformation is a key driver of economic growth and diversification that is in line with Qatar's 2030 National Vision.
  • Now in its 17th Edition, the Digital Transformation Series is coming to Qatar and is the ideal summit that will enable the public and private sectors to embrace technologies that will foster change and unlock operational efficiencies," said Rishikesh Shetty, CEO, of Exito Media Concepts, the organizer of the event.

First Patient Enrolled in AMIHOT III Trial Investigating ZOLL’s Supersaturated Oxygen Therapy in Heart Attack Patients

Retrieved on: 
Wednesday, September 7, 2022
Cardiology, Software, Health, FDA, Medical Devices, Hospitals, Technology, Clinical Trials, Mortality, Triangle, Patient, University, Asahi Kasei, Safety, Muscle tissue, Hospital, STEMI, PCI, Carbon, Ventilation, Solution, Infarction, Ammonia, Incidence, Heart failure, Volunteering, Physician, Diagnosis, Data management, Dialysis, EMS, Health care, Principal, MVO, Multimedia, LAD, Rehabilitation hospital, MD, WakeMed, Instagram, FDA, Percutaneous coronary intervention, Twitter, Hamad Medical Corporation, Sleep apnea, Reflow soldering, Health, Life, CPR, University of New Mexico, Pharmaceutical industry, Medical device, Facebook

The patient, treated at WakeMed Health & Hospitals in North Carolina, received SSO2 Therapy, the first FDA-approved therapy shown to significantly reduce the size of damaged tissue (infarct) following percutaneous coronary intervention (PCI).

Key Points: 
  • The patient, treated at WakeMed Health & Hospitals in North Carolina, received SSO2 Therapy, the first FDA-approved therapy shown to significantly reduce the size of damaged tissue (infarct) following percutaneous coronary intervention (PCI).
  • TherOx SSO2 Therapy is currently indicated for patients who suffer LAD STEMI heart attacks with a high mortality rate treated within six hours of symptom onset.
  • SSO2 Therapy has been shown to reduce relative infarct size damage to the heart muscle by 26% over standard of care.
  • Besides demonstrating the safety and effectiveness of SSO2 Therapy, additional endpoints include incidence of microvascular obstruction (MVO), and outcomes measures such as heart failure readmissions and quality-of-life measures.

Centers for Medicare & Medicaid Services (CMS) Issue New ICD-10-PCS Code for ZOLL Medical's TherOx SSO2 Therapy

Retrieved on: 
Thursday, July 14, 2022
Research, General Health, Professional Services, Pharmaceutical, Technology, Medical Devices, Hospitals, Science, Biotechnology, Insurance, FDA, Other Technology, Health, Health care, Ammonia, Data management, Life, Health information management, LAD, Solution, Asahi Kasei, Infarction, EMS, Muscle tissue, Atherosclerosis Risk in Communities, Patient, Supersaturation, Center, Institute for Community Studies, Mortality, Centers for Medicare & Medicaid Services, CPR, CMS, Diagnosis, STEMI, Cardiac muscle, Data collection, Medicare, Health, Angioplasty, Epidemiology, Atherosclerosis, FDA, Research, Hamad Medical Corporation, Hospital, Dialysis, Ventilation, Risk, Myocardial infarction, Sleep apnea, Classification, Pharmaceutical industry, Medical device

ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the Centers for Medicare & Medicaid Services (CMS) ICD-10 Coordination and Maintenance Committee has issued a new ICD-10-PCS code for TherOx SuperSaturated Oxygen (SSO2) Therapy.

Key Points: 
  • ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the Centers for Medicare & Medicaid Services (CMS) ICD-10 Coordination and Maintenance Committee has issued a new ICD-10-PCS code for TherOx SuperSaturated Oxygen (SSO2) Therapy.
  • The new code (5A0222C), for cardiac intra-arterial use, is effective for hospital discharges beginning October 1, 2022.
  • The code includes treatment of patients with left anterior descending ST-elevation myocardial infarction (LAD STEMI) heart attacks, which have higher mortality rates than other types of heart attacks.
  • TherOx and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries.

ETL becomes Lexica as it unveils new strategy for growth

Retrieved on: 
Tuesday, June 14, 2022
Science, Guy's and St Thomas' NHS Foundation Trust, ETL, DEFRA, Harwell Science and Innovation Campus, GSTT, Research, Lexicon, Pirbright Institute, Digital, City, NHS, COVID-19, Innovation, Solution, List of life sciences, King's Health Partners, Growth, Imperial College Healthcare NHS Trust, Health, Hamad Medical Corporation, NHS foundation trust, Strategic planning, Video game, Online gambling, Hospital, Public relations, Medicine

This follows record income of 12.4M in the financial year to 31 March 2022, up 23% on the previous financial year.

Key Points: 
  • This follows record income of 12.4M in the financial year to 31 March 2022, up 23% on the previous financial year.
  • The ambitious strategy will see Lexica further develop its existing services in seven priority growth areas: strategic planning services for life sciences as well as health; sustainability; data analytics; built asset life cycle; transition; digital; large healthcare programme and project management.
  • Tina Nolan, Managing Director, Lexica explained that the company took 'lexicon', meaning specialism-specific language, and pluralised it to reflect Lexica's two specialisms.
  • Its services include strategy and planning; property consultancy; cost management; project management; programme management; net zero transition; and infrastructure solutions.

Oneview Healthcare PLC Announces New Managing Director for Australia and New Zealand

Retrieved on: 
Tuesday, April 19, 2022
Managed Care, General Health, Health, Nursing, Oneview, Non-governmental organization, Caregiver, Hospital, Patient, Mark (given name), Hamad Medical Corporation, University of Southern Queensland, Bachelor of Science in Nursing, Queensland Health, Multimedia, University, Medicine

Oneview Healthcare Plc today announced that Colin Hackwood is joining the company as Managing Director for Australia and New Zealand effective immediately.

Key Points: 
  • Oneview Healthcare Plc today announced that Colin Hackwood is joining the company as Managing Director for Australia and New Zealand effective immediately.
  • View the full release here: https://www.businesswire.com/news/home/20220419006000/en/
    Colin Hackwood, new Managing Director for Australia and New Zealand (Photo: Business Wire)
    Prior to joining Oneview, Colin was Planning Director at the Victorian Health Building Authority where he led infrastructural planning and implementation projects.
  • For healthcare systems who lead on exemplary care, Oneview Healthcare plc provides digital tools for patients, families and caregivers to improve the care experience.
  • Oneview has partnered with leading healthcare systems in the US, Australia, the Middle East and Asia to unify the care experience, in 63 hospitals.